Pharvaris N.V. has announced its financial results for the third quarter of 2026, marking a significant moment for the company as it progresses in the biopharmaceutical sector. The report comes as Pharvaris prepares for the FDA's review of its lead product, deucrictibant, which aims to address unmet medical needs in treating bradykinin-mediated angioedema. This update is particularly relevant for stakeholders and competitors in the pharmaceutical preparations industry.

Company Overview

Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing novel oral bradykinin B2 receptor antagonists. The company is headquartered in Leiden, Netherlands, and trades on the Nasdaq under the ticker symbol PHVS. Pharvaris is classified under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. The firm is categorized as a large accelerated filer and has been actively filing with the SEC, including a recent submission of a Schedule 13G/A on November 13, 2026.

What the Filing Says

In its latest filing, Pharvaris reported that the New Drug Application (NDA) for deucrictibant IR is currently under review by the FDA, with a Prescription Drug User Fee Act (PDUFA) date set for April 23, 2027. The company also noted that topline data from part 1 of the pivotal Phase 3 study, CREAATE, evaluating deucrictibant XR for the prophylaxis of angioedema attacks is expected in the first quarter of 2027. Furthermore, Pharvaris is preparing the NDA dossier for deucrictibant XR, which is on track for submission in the first half of 2027.

Impact

This update is significant for various stakeholders, including investors, healthcare professionals, and patients who rely on effective treatments for bradykinin-mediated angioedema. The anticipated results from ongoing studies and the potential FDA approval could influence market dynamics within the biopharmaceutical sector, particularly for companies developing similar treatments.

What's Next

Pharvaris is expected to continue its momentum with further updates on its clinical trials and potential product launches. The filing does not specify what happens next, but the company is actively preparing for its first commercial launch and is building a capable commercial team to support its products.